n/a
Article Publish Status: FREE
Abstract Title:

Oridonin inhibits aberrant AKT activation in breast cancer.

Abstract Source:

Oncotarget. 2018 May 8 ;9(35):23878-23889. Epub 2018 Feb 1. PMID: 29844859

Abstract Author(s):

Bowen Sun, Geng Wang, Huidong Liu, Pian Liu, Waleed O Twal, Hiuwing Cheung, Steven L Carroll, Stephen P Ethier, Emily E Mevers, Jon Clardy, Thomas Roberts, Changbin Chen, Qian Li, Lanfeng Wang, Meixiang Yang, Jean J Zhao, Qi Wang

Article Affiliation:

Bowen Sun

Abstract:

Aberrant activation of phosphatidylinosito-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/AKT) signaling in cancer has led to pursuit of inhibitors for targeting this pathway. However, inhibitors of PI3K and AKT have failed to yield efficacious results without adverse effects. Here, we screened a library containing 441 authenticated traditional chinese medicine (TCM) plant extracts by examining their effect on cell viability of a human mammary epithelial cell line HMEC-PIK3CA, which expresses mutant PIK3CAand has constitutively active AKT signaling. We found that Oridonin, an extract from, reduced cell viability to the greatest extent. Oridonin binds to AKT1 and potentially functions as an ATP-competitive AKT inhibitor. Importantly, Oridonin selectively impaired tumor growth of human breast cancer cells with hyperactivation of PI3K/AKT signaling. Moreover, Oridonin prevented the initiation of mouse mammary tumors driven by PIK3CA. Our results suggest that Oridonin may serve as a potent and durable therapeutic agent for the treatment of breast cancers with hyperactivation of PI3K/AKT signaling.

Study Type : In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.